Redeye returns with an update following the Q1 report. We expect some negative impact on 2023 earnings due to higher costs. Our long-term view remains intact however, as we see good prospects for profitable growth within both business segments. Our Base case fair value is virtually unchanged at SEK2.7 suggesting an appealing potential from current share price levels.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/